Open Label Trial on the Safety and Efficacy of Sym001 in the Treatment of Immune Thrombocytopenic Purpura (ITP)
Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
This trial is designed as a multi-centre, single-dose, exploratory dose-finding, open label
trial evaluating the safety and efficacy of Sym001 in 4-9 consecutive cohorts. Subjects will
receive a single IV dose of Sym001.